timolol + brimonidine + dorzolamide + latanoprost

**Timolol + brimonidine + dorzolamide + latanoprost** is a quadruple fixed-combination ophthalmic solution designed for topical administration to treat elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It combines four agents with complementary mechanisms: **timolol** (non-selective beta-blocker) reduces aqueous humor production by blocking beta-adrenergic receptors in the ciliary epithelium; **brimonidine** (alpha-2 adrenergic agonist) decreases aqueous production and increases uveoscleral outflow; **dorzolamide** (carbonic anhydrase inhibitor) suppresses aqueous formation by inhibiting bicarbonate formation in the ciliary processes; and **latanoprost** (prostaglandin F2α analog) enhances uveoscleral outflow by increasing matrix metalloproteinase activity and remodeling extracellular matrix. This combination aims to provide superior 24-hour IOP control compared to dual or triple therapies, improving adherence by simplifying regimens and reducing preservative exposure, though specific commercial branding may vary and some formulations are compounded.[1][2][5][7][11]

Brand names

Tim-Brim-Dor-Lat

Other names

brimonidine + dorzolamide + latanoprost + timololdorzolamide + timolol + brimonidine + latanoprostTDB-Ltimolol + brimonidine + dorzolamide + latanoprostTimolol Brimonidine Dorzolamide Latanoprost Ophthalmic Solution Preservative-Free